Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies might help viral clearance, these patients could be at risk of severe complications if infected. Here, we report on an MS patient who had received rituximab for ~3 years. The patient was examined 5 days before the onset of coronavirus disease 2019 (COVID-19) symptoms and was admitted to the hospital 2 days after. She recovered 14 days after symptom onset despite having a 0% B lymphocyte count and not developing SARS-CoV-2 immunoglobulin G (IgG) antibodies.
1261 - 1264
B-cell-depleting therapy, COVID-19, Multiple sclerosis (MS), SARS-CoV-2 antibodies, cellular immune responses, rituximab, B-Lymphocytes, Betacoronavirus, CD4-CD8 Ratio, CD4-Positive T-Lymphocytes, Coronavirus Infections, Disease Progression, Female, Humans, Immunity, Cellular, Killer Cells, Natural, Lymphocyte Count, Middle Aged, Multiple Sclerosis, Chronic Progressive, Pandemics, Pneumonia, Viral, Rituximab